Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy
Thomas Müller(Johns Hopkins University), Dirk H. Busch(German Center for Infection Research), Simon Grassmann(Technical University of Munich), Tobias Feuchtinger(University of Freiburg), Sebastian Jarosch(Boehringer Ingelheim (Germany)), Kathrin Schumann(Institute for Advanced Study), Bettina E. Bernard(Institute of Medical Microbiology and Hygiene), Peter Steinberger(University of Vienna), Manuel Effenberger(Institute of Medical Microbiology and Hygiene), Monika Hammel(Institute of Medical Microbiology and Hygiene), M. Zeeshan Chaudhry(The University of Queensland), Theresa Käuferle(German Center for Infection Research), Immanuel Andrä(Technical University of Munich), Luka Čičin‐Šain(German Center for Infection Research), Justin Leube(Institute of Medical Microbiology and Hygiene), Ulrike Protzer(German Center for Infection Research), Kilian Schober(Friedrich-Alexander-Universität Erlangen-Nürnberg), Antje Malo, Michael Neuenhahn(Institute of Medical Microbiology and Hygiene)
Cited by 58
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
|Nature Communications|2016|727